Drugs / AMXT 1501
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05717153 | Oct 2023 → Jan 2027 expected | malignant glioma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03536728 | Jun 2018 → Dec 2022 | carcinoma | Aminex Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06465199 | May 2026 → May 2033 expected | Ewing sarcoma, atypical teratoid rhabdoid tumor, diffuse intrinsic pontine glioma, embryonal tumor with multilayered rosettes +2 | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07287917 | Jan 2026 → Feb 2028 expected | cutaneous melanoma, hormone receptor-positive breast cancer | Aminex Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05500508 | Nov 2022 → Dec 2024 | breast cancer, cervical cancer, colorectal cancer, diffuse midline glioma, H3 K27M-mutant +10 | Aminex Therapeutics, Inc. | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03077477 Comparator | Jun 2018 | neoplasm, poisoning | Aminex Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMXT 1501 | “AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment.” NCT05717153 ↗7“oral AMXT 1501 dicaprate (AMXT1501) in combination with DFMO” NCT03536728 ↗ |
| Known as | AMXT 1501 dicaprate | “The objective of this study is to determine the safety and tolerability of oral AMXT 1501 dicaprate (AMXT1501) in combination with IV DFMO in patients with advanced solid...” NCT05500508 ↗1“oral AMXT 1501 dicaprate (AMXT1501) in combination with DFMO” NCT03536728 ↗ |
| Action | Inhibit | “AMXT 1501, a potent inhibitor of polyamine transport” PMID 40913836 ↗ Sep 2025 |
| Modality | Small molecule | — CHEMBL474635 ↗ |
| Route | Oral | “orally administered” NCT03077477 ↗ |